Four cases of delayed radiation necrosis involving the CNS were found in a group of 46 patients irradiated for pituitary tumours over a six year period. This occurred in three of 11 patients with Cushing's disease representing an incidence of 27% in this group. There were no cases among 11 patients with acromegaly or among seven with prolactinomas. One case (6%) was found in the 17 patients with chromophobe adenomas. Standard doses of radiation were delivered to these patients and the findings support suggestions that the metabolic disturbances of Cushing's disease may reduce tolerance to radiation. Our results and a literature review indicate that if radiotherapy is used to treat Cushing's disease, the total dose should be less than 50 Gy at 2 Gy per day fractionation. (7 Neurol Neurosurg Psychiatry 1992;55:949-955) 
The difference in the reported incidence of DCRN following pituitary radiation may have a number of explanations. Studies vary markedly in terms of total dose, dose per fraction and duration of radiotherapy. Follow-up tends to be dispersed among neurosurgeons, radiotherapists, neurologists and endocrinologists, each group viewing treatment outcome from a different perspective. A causal relationship between the neurological deficit and radiotherapy may not be recognised or may be difficult to establish as the peak incidence of DCRN is one to three years after radiation,4 but it may not appear until many years later. DCRN has to be distinguished from tumour recurrence, the empty sella syndrome and coincidental cerebrovascular disease. This was particularly difficult in the era before CT scanning. Reported series often encompassed a long time span and analysis was based on retrospective case note reviews. It is likely that the discrepancy in the reported incidence of DCRN is partly due to failure to detect all cases.
In this study we carefully examined a group of patients irradiated at Westmead Hospital using modern radiotherapy techniques to assess the prevalence of DCRN.
Patients and methods Fifty one patients received radiotherapy for pituitary tumours at Westmead Hospital between January 1980 and December 1985.
Four had gone overseas and could not be reviewed and another refused to be seen. Of the remaining 46 patients, the subjects of the study, there were 11 cases of Cushing's disease, 11 of acromegaly, 7 prolactinomas and 17 patients with chromophobe adenomas. Clinical details are listed in table 1 . Seven had died. In these cases, physicians who had cared for them were contacted to discover details of their final illness. All surviving patients were seen by a neurologist (either JM or PGS) in 1987, at least one year after the completion of radiotherapy. During the review, the case notes were examined and a careful history was obtained from the patients and their relatives (if present) with particular emphasis on memory, behaviour changes, seizures, strokes or visual problems since the radiotherapy. A formal neurological examination followed with emphasis on visual field testing, both by confrontation and by testing for central desaturation with a red pin. hemiparesis. CT scan showed low density lesions in both internal capsules and a low density non-enhancing lesion in the left temporal lobe. She continued to deteriorate and was transferred to a nursing home. When reviewed there in 1987, she was demented and bedridden. The left hemiparesis was still evident and she had now developed blindness in her left eye with optic atrophy. This patient had many risk factors for stroke and her initial problems 17 months post radiotherapy were attributed to cerebrovascular disease. The subsequent development of optic atrophy and the progressive nature of her illness, involvement of both cerebral hemispheres and fits are more readily attributable to radiation necrosis than cerebrovascular disease.
Case 2 A 52 year old woman was diagnosed with Cushing's disease after she had been treated for hypertension for the preceding five years. A cerebral CT scan was normal. Radiotherapy was given after a brief trial of aminoglutethamide and metyrapone. A total dose of 50 Gy was delivered using a 3 field technique to a volume of 64 cubic centimetres with a daily fraction of 2-10 Gy (figure 2). TDF was 83 and CRE 1570 reu. During the radiotherapy she received metyrapone blockade with dexamethasone replacement. Eighteen months later, she suddenly lost the vision in her right eye. Initially there was a horizontal deficit with loss of the upper field but total blindness developed over a few days. Medications at the *CRE = cumulative radiation effect. This is a simple notation to normalise different schedules and regimes as a dimensionless number. It represents a summation of the effects of radiation fractions or groups of fractions with account being taken of the injury caused by prior fractions.24 Figure 3 The patient received 50 Gy with a daily Figure 4 The patient received 50 Gy to 7 x 7 cm fraction of 2 Gy via S x 5 cm paraUlel opposed fields.
parallel opposed fields with a daily fraction of 2 17 Gy.
time included aminoglutethamide, metyrapone and polaramine. When seen one month later, there was complete blindness in that eye due to optic atrophy. Visual acuity in her left eye was 6/15. When questioned, she complained of loss of recent memory. Visual evoked responses were absent from the right eye and there was a normal response on the left. Erythrocyte sedimentation rate was 11 millimetres per hour. Cranial CT and MRI scans were normal. Four months later she was admitted with failing vision in her left eye. She could no longer see television, read a book or distinguish faces. The visual acuity in the left eye had declined to 6/36 and both optic discs were now pale. Her ESR remained normal. A course of oral prednisone produced no improvement. Her memory problems have persisted. Case 3 A 61 year old woman presented with a five month history of headaches, difficulty climbing stairs and hypertension and was found to have Cushing's disease. A cerebral CT scan revealed a partially empty sella with a low density area within the inferior portion of the gland. She was treated with radiotherapy. The total dose was 50 Gy with a daily fraction of 2 Gy via 5 x 5 cm parallel opposed fields (figure 3). TDF was 82 and CRE 1550 reu. During the radiotherapy she received metyrapone and dexamethasone.
Fifteen months later she noted slight blurring of the vision in her left eye. This slowly progressed over the next six months until she could only detect hand movements and then deteriorated no further. A cerebral CT scan was unchanged. In 1987, she had evidence of left optic atrophy and also admitted to a recent decline in short term memory although she felt this had never been good. Visual evoked responses were absent on full and half field stimulation of the left eye and were poorly formed on stimulation of the right eye. This suggested either chiasmal or bilateral optic nerve damage, worse on the left. Medications at the time of assessment included aminoglutethamide, metyrapone, dexamethasone, metoprolol, spironolactone, premarin, calcium gluconate and mylanta. A subsequent cerebral CT scan in 1989 revealed a slight decrease in the size of the gland but the chiasm in all scans has remained above the sella. Case 4 This 61 year old man presented with bitemporal hemianopia. He was found to have a 3 centimetre pituitary tumour extending into the cavernous sinus and suprasellar regions. A chromophobe adenoma was incompletely removed through a right frontal craniotomy. In the immediate post-operative period, there was a haemorrhage in the region of the pituitary which was associated with generalised seizures. These were controlled by anti-convulsants. Hydrocephalus developed and a ventriculoperitoneal shunt was inserted. Radiotherapy started one month later. Repeat head CT scan showed the tumour continued to extend beyond the pituitary fossa. The patient had hypopituitarism and was receiving replacement dexamethasone. A midline dose of 50 Gy was applied in 23 daily fractions of 2 17 Gy to parallel pair fields of 7 x 7 cms (figure 4).
TDF was 83 and CRE 1550 reu. Six months later the tumour recurred (figure 5a). Following further attempts at tumour removal, the patient sustained a right frontal lobe infarct (figure 5b). Fourteen months after the radiotherapy he became confused and three months later there was a sudden deterioration in his level of consciousness. He spent most of his time asleep, had no spontaneous speech and mumbled incomprehensively when questioned. He continued to deteriorate and CT scans over the next three months revealed progressive ventricular dilatation (not relieved We feel that there is strong evidence that these patients had DCRN. However, they illustrate the difficulties in determining the real incidence of DCRN. None had pathological confirmation of the diagnosis. In cases 1-3, where the damage was primarily to the optic nerve or chiasm, the diagnosis has to rest on the clinical and radiological features as biopsy of an optic nerve would, in our view, be unethical. A biopsy of the left temporal lobe was not done in case 1, as this would have involved subjecting a demented, bedridden patient to an invasive procedure to make the diagnosis of a condition for which there is no treatment. The lack of adequate necropsy information on the seven patients who died is a reflection of the dispersion of follow up between different specialists and general practitioners. There was no central, systematic monitoring of their progress and no concerted effort to obtain an adequate post-mortem neuropathological examination. This would appear to be a particular problem with pituitary tumours and is likely to have occurred in previous studies.
Aristizabel et al''6-8 have previously reported that the chiasm is particularly vulnerable to radiotherapy in Cushing's disease. They encountered five cases of DCRN amongst 122 patients with pituitary tumours. Four had optic pathway damage and one brainstem necrosis. DCRN occurred only in patients who had received a total dose of between 46 Gy and 52 Gy, or individual fractions of more than 2 Gy. In this sub-group three of nine patients with Cushing's disease, one of four with acromegaly and one of 13 with chromophobe adenomas developed DCRN. A literature review revealed that of 14 cases of DCRN in patients with pituitary tumours, who had received what the authors regarded as acceptable radiation doses, seven had Cushing's disease. Visual pathway damage was the most common problem, presenting either alone or in combination with cerebral damage. The authors postulated that the high circulating steroid levels present in Cushing's disease act as a radiosensitiser. It was also suggested that hypertension might have a role27 28 and that patients with acromegaly may be at increased risk.
Uncertainty still exists as to the optimum dose of radiotherapy for pituitary adenomas. Existing guidelines have evolved by inference from reports of complications attributed to excessive doses. Unfortunately in many studies there has been considerable variation in radiotherapy technique. In our study a parallel opposed pair of bitemporal fields was used in 38 of 46 34 In a trial of adjuvant therapy for breast cancer, seven of 13 patients treated with radiation and medroxyprogesterone developed radiation induced oesophagitis and/or pneumonitis whereas this occurred in only one of nine treated with the same doses of radiation alone (p < 0-05).
There was one other patient in our study who developed DCRN. He had a large, very aggressive chromophobe adenoma. Three attempts at surgical removal were unsuccessful and each was associated with complications. This may well have predisposed to the subsequent development of DCRN. In any case, it is most unlikely he would have survived had radiotherapy not been given and DCRN must be seen here as an acceptable risk in the context of a desperate situation. Of the other six patients who died, the diagnosis of DCRN was considered in one but the evidence is not strong. There does not seem to be a "hidden" incidence of DCRN in this group.
In conclusion, we feel it is important to consider the type of tumour when irradiating pituitary adenomas. The metabolic disturbances of Cushing's disease pose different problems to the local destruction of a chromophobe adenoma and may produce an altered biological response to radiation. There has been a tendency to deliver similar doses of radiation irrespective of the patients condition or tumour type. Therapy should be individualised according to the patient's problems. An incidence of optic pathway damage of 27% is unacceptable and we feel that the total dose should be reduced to less than 50 Gy in Cushing's disease but cannot from this data determine a "safe" dose.
